



Xenotransplantation: Today and Tomorrow

Denner J*

Head of Laboratory, Center HIV and Retrovirology, Robert Koch Institute, Berlin, Germany

The Need

Xenotransplantation using pig cells, tissues or organs is at present thought to be the best approach to alleviate the increasing shortage of human tissues and organs for the treatment of tissue and organ failure. This shortage is the reason that approximately 25% of the patients on a waiting list die before they could be treated with an appropriate donor organ. In the US, 30,974 organ transplants were performed in 2015, however 118,066 people need a lifesaving organ transplant [1].

Xenotransplantation using pig islet cells may be also the most effective solution for the treatment of diabetes. In 2012, 29.1 million Americans, or 9.3% of the population, had diabetes, among them approximately 1.25 million children and adults with type 1 diabetes. Although the treatment of diabetes type 1 with insulin was quite successful in the past, nevertheless complications were observed mainly due to insufficient compliance of the patients. Among the complications described were amputations of the limbs and blindness. The total costs of diagnosed diabetes in the US in 2012 were 245 billion dollars, most of these costs were spend for the treatment of complications, the expenditure for insulin was relatively low [2].

Pigs are for numerous reasons (size, physiology, easily genetically modified, cloned, large number of progeny) the most preferred donor animal for xenotransplantation [3].

The Problems

As in the case of allotransplantation, the main problem in xenotransplantation is the rejection of the immunologically unrelated organ. As well-known, the relatedness of the donor and recipient are the main factor determining the survival of the transplant, then more genetic mismatches, than shorter the survival time.

A new problem not described for allotransplantation is the hyper acute rejection (HAR) [4]. Humans develop antibodies against certain sugar residues present on the cell surface of bacteria, among them galactose α 1,3-galactose (α -gal) and 2 N-glycoylneuraminic acid-terminated gangliosides (Neu5Gc) [5]. These sugar residues are not present on human cells, but on cells from many animals including pigs. Transplanted pig tissues or organs carrying such sugar residues will be destroyed by these pre-existing antibodies and the human complement system in a few minutes.

Another potential risk associated with xenotransplantation is the possible transmission of porcine microorganisms (bacteria, fungi, protozoa, and viruses) which may lead to diseases, so-called zoonoses [6]. Transmission of microorganisms was also reported during allotransplantation, including human immunodeficiency virus-1 (HIV-1), human cytomegalovirus (HCMV) and rabies virus [7]. Whereas human pathogens are well adapted to humans, porcine microorganisms are not and it is unclear, whether they can infect human cells and replicate in humans. For some porcine viruses a zoonotic potential was described, for example for hepatitis E virus (HEV), genotype 3, which at least in immuno suppressed and patients with a pre-existing liver failure induces a chronic infection and disease [8,9]. Others, such as the porcine cytomegalovirus (PCMV) may be pathogenic without infecting cells of the host. In preclinical trials, transplanting pig kidneys in cynomolgus monkeys and baboons, the presence of PCMV led to an early transplant failure, possibly due to cytokines produced in response to viral antigens [10].

Finally, the porcine endogenous retroviruses (PERVs) are integrated in the pig genome, are produced as infectious virus particles and may infect certain types of human cells [11,12]. PERV-A and PERV-B are integrated in the genome of all pigs, whereas PERV-C was found in many, but not all pigs. In addition, recombinants between PERV-A and PERV-C were found in pigs which were highly replication-competent. PERVs like most other retroviruses may theoretically induce tumours and/or immuno deficiencies, but their zoonotic potential is yet unknown and in preclinical pig-to-non-human primate preclinical trials and in first clinical trials, no PERV transmission was observed [12-15].

OPEN ACCESS

*Correspondence:

Denner J, Head of Laboratory, Center HIV and Retrovirology, Robert Koch Institute, Nordufer 20, 13353 Berlin, Germany, Tel: +49-(0)30-18754-2800; E-mail: dennerj@rki.de

Received Date: 08 May 2017

Accepted Date: 19 May 2017

Published Date: 27 May 2017

Citation:

Denner J. Xenotransplantation: Today and Tomorrow. *Ann Transplant Res.* 2017; 1(1): 1002.

Copyright © 2017 Denner J. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Another problem, the physiological incompatibility cannot be evaluated at present since the survival time of the transplanted organs is too short to analyse its long-term functionality.

The Solutions

To overcome the immunological rejection including HAR, genetically modified pigs were created. There are two types of genetic modifications, first knock-out animals in which genes encoding enzymes bringing the above mentioned sugar residues on the surface of pig cells, e.g., α 1,3 galactosyltransferase (α 1,3GT), were knocked out (GTKO), and second, transfection and expression of human genes responsible for complement activation and other processes of immune rejection and of coagulation [16,17].

To overcome the risk of transmission of porcine microorganisms, elimination programs were developed based on selection, treatment, vaccination, Cesarean delivery, early weaning and embryo transfer [6,9,10,18]. PERVs cannot be eliminated by these mechanisms since the proviral DNA is integrated in the genome of all pig cells, therefore different strategies have been developed to prevent PERV transmission during xenotransplantation including a PERV-specific vaccine [19,20], antiretroviral drugs [21,22], transgenic pigs expressing a PERV-specific small-interfering (si)RNA [23-25] and genome editing using zinc finger nucleases (ZFN) [26] or CRISPR/Cas (clustered regularly interspaced short palindromic repeats, CRISPR-associated) [27].

The Achievements and the Future

First of all, multi transgenic pigs were successfully created in order to prevent rejection of pig cells and organs. Second, new pharmaceutical immuno suppression regimens were introduced, also in order to prevent rejection. Based on these achievements, longer survival times of transplanted pig hearts, kidneys, liver, and islet cells have been observed in preclinical trials [28-31]. Heterotopic heart transplants from GTKO, CD46 and thrombomodulin genetically modified pigs survived up to 945 days in baboons (median survival time 298 days) [32]. The longest survival time of orthotopic heart transplantation using GTKO/CD55 pigs was 57 days [33], the longest survival time of pig kidney transplants 310 days [34] and the survival time of pig islet cells was 950 days (median 303) [35]. Third, new and sensitive methods have been developed to screen the donor pigs for potential zoonotic microorganisms, making xenotransplantation eventually safer compared with allotransplantation, where in rare cases HIV-1, rabies virus, HCMV, and other pathogens have been transmitted [7]. Although PCMV has been transmitted in pig-to-non-human primate kidney and heart transplantation [36-39], no transmission of porcine viruses was observed in first pig islet cell transplantation in humans [13-15]. The transmission of PCMV into cynomolgus monkeys and baboons however was associated with a significant reduction of the survival time of the pig transplant [36,37]. Fourth, the discussion on ethical aspects is on-going, an updated consensus document on how to perform safe and efficient xenotransplantation was prepared by the scientific community, and in several countries a national regulatory frame work was prepared [40]. All these achievements will allow clinical application of xenotransplantation in the near future.

References

1. <https://www.unos.org/data/>
2. <http://www.diabetes.org/diabetes-basics/statistics/?loc=superfooter>

3. Hammer C. Xenotransplantation-will it bring the solution to organ shortage? *Ann Transplant.* 2004;9(1):7-10.
4. Cooper DK, Ekser B, Tector AJ. Immuno biological barriers to xenotransplantation. *Int J Surg.* 2015;23:211-6.
5. Galili U. The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. *Immunol Cell Biol.* 2005;83:674-86.
6. Denner J, Mueller NJ. Preventing transfer of infectious agents. *Int J Surg.* 2015;23:306-11.
7. Fishman JA. Infection in organ transplantation. *Am J Transplant.* 2017;17(4):856-79.
8. Pavio N, Meng XJ, Doceul V. Zoonotic origin of hepatitis E. *Curr Opin Virol.* 2015;10:34-41.
9. Denner J. Xenotransplantation and hepatitis E virus. *Xenotransplantation.* 2015;22(3):167-73.
10. Denner J. Xenotransplantation and porcine cytomegalovirus. *Xenotransplantation.* 2015;22(5):329-35.
11. Scobie L, Takeuchi Y. Porcine endogenous retrovirus and other viruses in xenotransplantation. *Curr Opin Organ Transplant.* 2009;14(2):175-9.
12. Denner J, Tönjes RR. Infection barriers to successful xenotransplantation focusing on porcine endogenous retroviruses. *Clin Microbiol Rev.* 2012;25(2):318-43.
13. Garkavenko O, Croxson MC, Irgang M, Karlas A, Denner J, Elliott RB. Monitoring for presence of potentially xenotic viruses in recipients of pig islet xenotransplantation. *J Clin Microbiol.* 2004;42(11):5353-6.
14. Wynyard S, Nathu D, Garkavenko O, Denner J, Elliott R. Microbiological safety of the first clinical pig islet xenotransplantation trial in New Zealand. *Xenotransplantation.* 2014;21(4):309-23.
15. Morozov VA, Wynyard S, Matsumoto S, Abalovich A, Denner J, Elliott R. No PERV transmission during a clinical trial of pig islet cell transplantation. *Virus Res.* 2017;227:34-40.
16. Niemann H, Petersen B. The production of multi-transgenic pigs: update and perspectives for xenotransplantation. *Transgenic Res.* 2016;25(3):361-74.
17. Klymiuk N, Aigner B, Brem G, Wolf E. Genetic modification of pigs as organ donors for xenotransplantation. *Mol Reprod Dev.* 2010;77(3):209-21.
18. Denner J, Mankertz A. Porcine circoviruses and xenotransplantation. *Viruses.* 2017;9(4):83.
19. Fiebig U, Stephan O, Kurth R, Denner J. Neutralizing antibodies against conserved domains of p15E of porcine endogenous retroviruses: basis for a vaccine for xenotransplantation? *Virology.* 2003;307(2):406-13.
20. Kaulitz D, Fiebig U, Eschricht M, Wurzbacher C, Kurth R, Denner J. Generation of neutralising antibodies against porcine endogenous retroviruses (PERVs). *Virology.* 2011;411(1):78-86.
21. Stephan O, Schwendemann J, Specke V, Tacke SJ, Boller K, Denner J. Porcine endogenous retroviruses (PERVs): generation of specific antibodies, development of an immuno peroxidase assay (IPA) and inhibition by AZT. *Xenotransplantation.* 2001;8(4):310-6.
22. Argaw T, Colon-Moran W, Wilson C. Susceptibility of porcine endogenous retrovirus to anti-retroviral inhibitors. *Xenotransplantation.* 2016;23(2):151-8.
23. Semaan M, Kaulitz D, Petersen B, Niemann H, Denner J. Long-term effects of PERV-specific RNA interference in transgenic pigs. *Xenotransplantation.* 2012;19(2):112-21.
24. Ramsoondar J, Vaught T, Ball S, Mendicino M, Monahan J, Jobst P, et al. Production of transgenic pigs that express porcine endogenous retrovirus

- small interfering RNAs. *Xenotransplantation*. 2009;16(3):164-80.
25. Dieckhoff B, Petersen B, Kues WA, Kurth R, Niemann H, Denner J. Knockdown of porcine endogenous retrovirus (PERV) expression by PERV-specific shRNA in transgenic pigs. *Xenotransplantation*. 2008;15(1):36-45.
26. Semaan M, Ivanusic D, Denner J. Cytotoxic effects during knock out of multiple porcine endogenous retrovirus (PERV) sequences in the pig genome by zinc finger nucleases (ZFN). *PLoS One*. 2015;10(4):e0122059.
27. Yang L, Güell M, Niu D, George H, Lesha E, Grishin D, et al. Genome-wide inactivation of porcine endogenous retroviruses (PERVs). *Science*. 2015;350(6264):1101-4.
28. Azimzadeh AM, Kelishadi SS, Ezzelarab MB, Singh AK, Stoddard T, Iwase H, et al. Early graft failure of GalTKO pig organs in baboons is reduced by expression of a human complement pathway-regulatory protein. *Xenotransplantation*. 2015;22(4):310-6.
29. Cowan PJ, Tector AJ. The resurgence of xenotransplantation. *Am J Transplant*. 2017.
30. Cooper DK, Satyananda V, Ekser B, van der Windt DJ, Hara H, Ezzelarab M, et al. Progress in pig-to-non-human primate transplantation models (1998-2013): a comprehensive review of the literature. *Xenotransplantation*. 2014;21(5):397-419.
31. Denner J. Recent progress in xenotransplantation, with emphasis on virological safety. *Ann Transplant*. 2016;21:717-27.
32. Mohiuddin MM, Singh AK, Corcoran PC, Thomas ML 3rd, Clark T, Lewis BG, et al. Chimeric 2C10R4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.hCD46.hTBM pig-to-primate cardiac xenograft. *Nat Commun*. 2016;7:11138.
33. Byrne GW, Du Z, Sun Z, Asmann YW, McGregor CG. Changes in cardiac gene expression after pig-to-primate orthotopic xenotransplantation. *Xenotransplantation*. 2011;18(1):14-27.
34. Wijkstrom M, Iwase H, Paris W, Hara H, Ezzelarab M, Cooper DK. Renal xenotransplantation: experimental progress and clinical prospects. *Kidney Int*. 2017;91(4):790-96.
35. Shin JS, Kim JM, Kim JS, Min BH, Kim YH, Kim HJ. Long-term control of diabetes in immuno suppressed nonhuman primates (NHP) by the transplantation of adult porcine islets. *Am J Transplant*. 2015;15(11):2837-50.
36. Sekijima M, Waki S, Sahara H, Tasaki M, Wilkinson RA, Villani V, et al. Results of life-supporting galactosyl transferase knockout kidneys in cynomolgus monkeys using two different sources of galactosyl transferase knockout swine. *Transplantation*. 2014;98(4):419-26.
37. Yamada K, Tasaki M, Sekijima M, Wilkinson RA, Villani V, Moran SG, et al. Porcine cytomegalovirus infection is associated with early rejection of kidney grafts in a pig to baboon xenotransplantation model. *Transplantation*. 2014;98(4):411-8.
38. Abicht JM, Mayr TA, Reichart B, Plotzki E, Güthoff S, Falkenau A, et al. Hepatic failure after pig heart transplantation into a baboon: no involvement of porcine hepatitis E virus. *Ann Transplant*. 2016;21:12-6.
39. Morozov VA, Abicht JM, Reichart B, Mayr T, Guethoff S, Denner J. Active replication of porcine cytomegalovirus (PCMV) following transplantation of a pig heart into a baboon despite undetected virus in the donor pig. *Ann Virol Res*. 2016;2(3):1018.
40. Cozzi E, Tönjes RR, Gianello P, Bühler LH, Rayat GR, Matsumoto S, et al. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 1: update on national regulatory frameworks pertinent to clinical islet xenotransplantation. *Xenotransplantation*. 2016;23(1):14-24.